Discovery of metastasis-associated biomarkers in ovarian cancer using SELDI-TOF: An in vitro and clinical study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bast RC Jr. Status of tumour markers in ovarian cancer screening. J Clin Oncol 2003; 21(10 Suppl): 200s–205s.
Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002; 38: 2435–2445.
Ashworth A, Balkwill F, Bast RC Jr, et al. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 2008; 108: 652–657.
Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572–577.
Zhang Z, Bast RC Jr, Yu YH, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882–5890.
Mou HZ, Xu SH, Zhang YY, et al. Establishment of a human ovarian cancer cell line (HO-8910) and its characterization. Zhonghua Fuchanke Zazhi 1994; 29: 162–164 (Chinese).
Xu SH, Qian LJ, Mou HZ, et al. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 1999; 18: 233–239.
Xia L, Cai WL, Zhang LJ, et al. The preliminary analysis of distinct proteins for different subtypes of lung cancer cells lines. Xiandai Yiqi 2004; 10: 13–17 (Chinese).
Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004; 10: 1625–1632.
XU Y. Research advance of protein fingerprinting technology in laboratory diagnosis and clinical medicine. Jichu Yixue Yu Linchuang 2007; 27: 134–142 (Chinese).
Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835–1843.
Petricoin EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576–1578.
Lawrie LC, Curran S, McLeod HL, et al. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001; 54: 253–258.
Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296–1304.
Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005;201: 479–486.
Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006; 131: 630–639.
Sagiv E, Kazanov D, Arber N, et al. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother 2006; 60: 280–284.
Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005; 65: 10783–10793.
Runz S, Keller S, Rupp C, et al. Malignant ascitesderived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007; 107: 563–571.
Kwon GY, Ha H, Ahn G, et al. Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69: 1150–1156.